Posting Date: January 5, 2021

Closing Date: January 15, 202 11:30 a.m. ET

Reference Number: 21-013966

To: NCI Bid Board

From: Tanya Alfred
NCI CCR P-ARC
Tanya.alfred@nih.gov

Subject: NCI Bid Board Posting – Biological Kits

The Surgery Branch (SB) of the National Cancer Institute (NCI) is a combined laboratory and clinical research unit devoted to the development of innovative cancer immunotherapies and their translation to the treatment of patients with cancer. Efforts run the gamut from basic studies of cancer immunology to the conduct of clinical immunotherapy trials for patients with metastatic cancer. The Surgery Branch was responsible for the development of interleukin-2 (IL-2), the first effective immunotherapy in humans, the development of cell transfer immunotherapies for melanoma and other solid cancers, the first insertion of foreign genes into humans and the first development of effective human cancer immunotherapies based on the genetic engineering of autologous lymphocytes with genes encoding anti-tumor T cell receptors or chimeric antigen receptors.

The SB seeks to procure fifty-nine (59) G-Rex100 Gas Permeable Cell Culture Device (3-Pack Box).

The National Cancer Institute plans to purchase fifty-nine (59) G-Rex100 Gas Permeable Cell Culture Device (3-Pack Box) from Wilson Wolf Manufacturing Corporation. This is not a request for competitive quotation. However, if any interested party believes it can meet the attached requirements, it may submit a statement of capabilities. The capability statement must be in writing and must contain information and material in sufficient detail to allow NCI to determine is the party can fully meet this requirement. The capability statement must be received in the contracting office by 11:30 AM on January 15, 2021 ET. A determination by the Government not to compete this requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement.

Sole Source Justification:

The Surgery Branch, National Cancer Institute (SB/NCI) has an ongoing clinical program using adoptive cell transfer therapy for the treatment of patients with metastatic cancer. The cell production laboratory of the SB/NCI uses a number of techniques to identify, purify and expand tumor reactive T lymphocytes from patients with advanced cancer. For adoptive transfer protocols only equipment and reagents that are produced in accordance with good manufacturing practices (GMP) can be utilized to expand patient cells, as mandated by the FDA. Previously, we used Lifecell bags from Baxter in our protocols to expand patient cells; however, Baxter has now discontinued the manufacture of Lifecell bags. Wilson Wolf Manufacturing produces a series of gas permeable flasks which have been used successfully to expand patient cells for adoptive cell therapy. These flasks are critical for the successful expansion of patient cells, to high densities, under static conditions, while providing enhanced aeration.

Attached Documents:
SF18
Statement of Work
FAR Clause 52.213-4 Simplified Acquisitions Terms and Conditions (JAN 2014) is applicable and available in full text upon request